发布求助
文献互助 智能选刊 最新文献

US Cardiology Review最新文献

筛选
英文 中文
Artificial Intelligence in Cardiac Imaging 人工智能在心脏成像中的应用
US Cardiology Review Pub Date : 2019-05-21 DOI: 10.15420/usc.2019.19.2
K. Seetharam, S. Shrestha, P. Sengupta
{"title":"Artificial Intelligence in Cardiac Imaging","authors":"K. Seetharam, S. Shrestha, P. Sengupta","doi":"10.15420/usc.2019.19.2","DOIUrl":"https://doi.org/10.15420/usc.2019.19.2","url":null,"abstract":"Machine learning (ML), a subset of artificial intelligence, is showing promising results in cardiology, especially in cardiac imaging. ML algorithms are allowing cardiologists to explore new opportunities and make discoveries not seen with conventional approaches. This offers new opportunities to enhance patient care and open new gateways in medical decision-making. This review highlights the role of ML in cardiac imaging for precision phenotyping and prognostication of cardiac disorders.","PeriodicalId":37809,"journal":{"name":"US Cardiology Review","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46178366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Baroreflex Activation Therapy for Resistant Hypertension and Heart Failure 压力反射激活疗法治疗顽固性高血压和心力衰竭
US Cardiology Review Pub Date : 2019-04-09 DOI: 10.15420/usc.2019.13.2
Deepak L. Bhatt, A. M. D. Kristensen, M. Pareek, M. Olsen
{"title":"Baroreflex Activation Therapy for Resistant Hypertension and Heart Failure","authors":"Deepak L. Bhatt, A. M. D. Kristensen, M. Pareek, M. Olsen","doi":"10.15420/usc.2019.13.2","DOIUrl":"https://doi.org/10.15420/usc.2019.13.2","url":null,"abstract":"Hypertension and heart failure are important contributors to global morbidity and mortality. Despite therapeutic lifestyle and pharmacological measures, a significant proportion of people with hypertension do not reach treatment targets. Patients with resistant or poorly controlled hypertension are at significantly increased risk of cardiovascular events, including heart failure. Since dysfunction of the sympathetic nervous system appears to play a key role in the development and progression of both hypertension and heart failure, these patients may benefit from treatment modalities aimed at reducing sympathetic function. The purpose of this paper is to provide an overview of baroreflex activation therapy as a potential treatment strategy in patients with resistant hypertension or heart failure.","PeriodicalId":37809,"journal":{"name":"US Cardiology Review","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46936259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome 化疗诱导Takotsubo综合征患者的临床特点及预后
US Cardiology Review Pub Date : 2019-03-19 DOI: 10.15420/usc.2019.10.1
K. Storey, S. Sharkey
{"title":"Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome","authors":"K. Storey, S. Sharkey","doi":"10.15420/usc.2019.10.1","DOIUrl":"https://doi.org/10.15420/usc.2019.10.1","url":null,"abstract":"Chemotherapy treatment of malignancy accounts for 1–2% of takotsubo syndrome (TS) triggers. Women comprise 60–70% of patients with chemotherapy-associated TS, a distinctly lower prevalence than the 90% female prevalence in TS overall. Fluorouracil is the most commonly reported TS-triggering chemotherapeutic agent, although this must be interpreted in the context of the frequency of worldwide use of this agent. The onset of TS relative to chemotherapy initiation is quite variable, ranging from the initial administration to subsequent chemotherapy cycles several weeks beyond initiation. Limited information suggests chemotherapy can be safely reinitiated once the patient has recovered from the initial TS event. Having a TS event in the setting of chemotherapy treatment for malignancy is associated with substantial mortality.","PeriodicalId":37809,"journal":{"name":"US Cardiology Review","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48540859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Effect of the Extent of Cardiac Damage on Transcatheter Aortic Valve Replacement Outcome: A New Aortic Stenosis Staging System 心脏损伤程度对经导管主动脉瓣置换术结果的影响:一种新的主动脉瓣狭窄分期系统
US Cardiology Review Pub Date : 2019-03-11 DOI: 10.15420/usc.2019.9.1
M. Fukui, J. Cavalcante
{"title":"Effect of the Extent of Cardiac Damage on Transcatheter Aortic Valve Replacement Outcome: A New Aortic Stenosis Staging System","authors":"M. Fukui, J. Cavalcante","doi":"10.15420/usc.2019.9.1","DOIUrl":"https://doi.org/10.15420/usc.2019.9.1","url":null,"abstract":"Severe aortic stenosis (AS) causes chronic pressure overload of the left ventricle (LV), resulting in progressive cardiac change that can extend beyond the LV. A new AS staging classification has been recently proposed encompassing the extent of cardiac changes in AS. The AS staging classification has important prognostic implications for clinical outcomes after aortic valve replacement. This article introduces the AS staging system and demonstrates the association of the extent of cardiac change with outcomes after transcatheter aortic valve replacement.","PeriodicalId":37809,"journal":{"name":"US Cardiology Review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41939980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can Early Management of Hypertension by General Practitioners Improve Outcome? 全科医生早期管理高血压能改善预后吗?
US Cardiology Review Pub Date : 2019-01-31 DOI: 10.15420/USC.2019.5.1
Deborah L. Nadler, A. Poppas
{"title":"Can Early Management of Hypertension by General Practitioners Improve Outcome?","authors":"Deborah L. Nadler, A. Poppas","doi":"10.15420/USC.2019.5.1","DOIUrl":"https://doi.org/10.15420/USC.2019.5.1","url":null,"abstract":"Hypertension and its cardiovascular sequelae remain one of the major causes of death and disability worldwide, and the prevalence of hypertension in the US and Europe is high. Hypertension is a leading modifiable risk factor for cardiovascular events. Pharmacological approaches and lifestyle modification to treat hypertension early have been consistently shown to improve cardiovascular outcomes in primary and secondary prevention. Recent guidelines recommend initiating treatment at lower blood pressure levels, with normal blood pressure being defined as <120/80 mmHg. Calculating risk using a score such as the Atherosclerotic Cardiovascular Disease Risk Calculator is important to enable the general practitioner to give appropriate, individualized care.","PeriodicalId":37809,"journal":{"name":"US Cardiology Review","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47530152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Everything in Moderation: Investigating the U-Shaped Link Between HDL Cholesterol and Adverse Outcomes 一切适度:调查高密度脂蛋白胆固醇和不良后果之间的u型关系
US Cardiology Review Pub Date : 2019-01-27 DOI: 10.15420/USC.2019.3.2
Marc P Allard-Ratick, P. Sandesara, A. Quyyumi, L. Sperling
{"title":"Everything in Moderation: Investigating the U-Shaped Link Between HDL Cholesterol and Adverse Outcomes","authors":"Marc P Allard-Ratick, P. Sandesara, A. Quyyumi, L. Sperling","doi":"10.15420/USC.2019.3.2","DOIUrl":"https://doi.org/10.15420/USC.2019.3.2","url":null,"abstract":"Despite historical evidence suggesting an inverse association between HDL cholesterol (HDL-C) and adverse cardiovascular events, pharmacological efforts to increase HDL-C and improve outcomes have not been successful. Recently, a U-shaped association between HDL-C and adverse events has been demonstrated in several population cohorts, further complicating our understanding of the clinical significance of HDL. Potential explanations for this finding include genetic mutations linked to very high HDL-C, impaired HDL function at high HDL-C levels, and residual confounding. However, our understanding of this association remains premature and needs further investigation.","PeriodicalId":37809,"journal":{"name":"US Cardiology Review","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46545891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Role of Drug-coated Balloons in Small-vessel Coronary Artery Disease 药物包被球囊在小血管冠状动脉疾病中的作用
US Cardiology Review Pub Date : 2019-01-27 DOI: 10.15420/USC.2019.4.1
M. Megaly, M. Saad, E. Brilakis
{"title":"Role of Drug-coated Balloons in Small-vessel Coronary Artery Disease","authors":"M. Megaly, M. Saad, E. Brilakis","doi":"10.15420/USC.2019.4.1","DOIUrl":"https://doi.org/10.15420/USC.2019.4.1","url":null,"abstract":"Percutaneous coronary intervention of small-vessel coronary artery disease (SVD) remains challenging due to difficulties with device delivery and high restenosis rate, even with the use of newer-generation drug-eluting stents. Drug-coated balloons represent an attractive emerging percutaneous coronary intervention option in patients with SVD. Potential advantages of drug-coated balloons in SVD include enhanced deliverability because of their small profile, avoidance of foreign-body implantation, and shorter duration of dual antiplatelet therapy.","PeriodicalId":37809,"journal":{"name":"US Cardiology Review","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46835148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Percutaneous Coronary Intervention: Developments in the Last 12 Months 经皮冠状动脉介入治疗：过去12个月的进展
US Cardiology Review Pub Date : 2019-01-16 DOI: 10.15420/USC.2019.1.1
R. Davies, J. Abbott
{"title":"Percutaneous Coronary Intervention: Developments in the Last 12 Months","authors":"R. Davies, J. Abbott","doi":"10.15420/USC.2019.1.1","DOIUrl":"https://doi.org/10.15420/USC.2019.1.1","url":null,"abstract":"In 2018, there were several studies that significantly added to the field of interventional cardiology. Research was focused on understanding the role of percutaneous coronary intervention (PCI) in various clinical syndromes, optimizing outcomes for high-risk lesion subsets, and building an evidence base for greater adoption of PCI guided by physiology and intracoronary imaging. In the area of innovation, novel and iterative developments in drug-eluting stents (DES) and scaffold platforms were compared with current generation DES. This article summarizes the research from last year which has had the most impact on PCI techniques and clinical care.","PeriodicalId":37809,"journal":{"name":"US Cardiology Review","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49356276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Next 10 Years in Atrial Fibrillation 心房颤动的未来10年
US Cardiology Review Pub Date : 2018-12-18 DOI: 10.15420/USC.2018.21.2
Jeffrey L. Turner, N. Marrouche
{"title":"The Next 10 Years in Atrial Fibrillation","authors":"Jeffrey L. Turner, N. Marrouche","doi":"10.15420/USC.2018.21.2","DOIUrl":"https://doi.org/10.15420/USC.2018.21.2","url":null,"abstract":"Predicting future advancements in arrhythmia management – specifically AF – with any certainty is impossible. The clinical approach to AF has changed markedly since the turn of the century in ways that could never have been foreseen, but the current methods of identification and treatment remain far from perfect. Over the next decade we expect significant continued progress in AF management. However, if asked to forecast the future, we consider it wise to predict advancements in the nearer term. We believe there will be widespread expansion in digital health and mobile devices, altering the way we detect and monitor the arrhythmia. We expect substantial growth in advanced MRI to aid in early detection, evaluation, and possibly non-invasive treatment of AF substrate. We imagine there will be increasing focus on individual populations to identify at-risk groups and personalize early management. We also anticipate improvement in anticoagulation employment and left atrial appendage modification. Finally, recognizing the benefit of improvement in modifiable risk factors such as mandatory tobacco cessation and weight loss in obese patients, we predict that reimbursement will be dependent on successfully addressing modifiable risk. For now, several questions remain unanswered, and while no one can predict the next 10 years in AF, there is, without doubt, an abundance of opportunity.","PeriodicalId":37809,"journal":{"name":"US Cardiology Review","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47560066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcatheter Edge-to-edge Repair of Severe Tricuspid Regurgitation 经导管边缘对边缘修复严重三尖瓣返流
US Cardiology Review Pub Date : 2018-12-13 DOI: 10.15420/USC.2018.20.1
Shu-I. Lin, M. Miura, F. Maisano, M. Zuber, M. Gavazzoni, E. Ho, A. Pozzoli, M. Taramasso
{"title":"Transcatheter Edge-to-edge Repair of Severe Tricuspid Regurgitation","authors":"Shu-I. Lin, M. Miura, F. Maisano, M. Zuber, M. Gavazzoni, E. Ho, A. Pozzoli, M. Taramasso","doi":"10.15420/USC.2018.20.1","DOIUrl":"https://doi.org/10.15420/USC.2018.20.1","url":null,"abstract":"Despite the increasing knowledge of the long-term adverse consequence of severe tricuspid regurgitation (TR), most patients with moderate- to-severe TR are still treated conservatively because of the high risk of surgery. Percutaneous procedures have emerged as an attractive alternative treatment. Transcatheter edge-to-edge repair is a validated technique to treat mitral regurgitation. In recent years, the same concept has been applied to patients with TR and prohibitive operative risk. Early trials have shown feasibility and safety. More clinical experiences and long-term results are still being gathered. In this article, we provide an overview of transcatheter edge-to-edge repair and look at the current evidence and clinical results regarding procedure.","PeriodicalId":37809,"journal":{"name":"US Cardiology Review","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49284569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信